The relationship between bone mineral density and levels of RANKL,osteoprotegerin and cathepsin-K in patients with rheumatoid arthritis by Gökhan Çakırca et al.
G. Çakırca, et al. BMD, RANKL, osteoprotegerin and Cathepsin-K in rheumatoid arthritis 479
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 39, No 4, 479-484
1 Ceylanpınar State Hospital, Department of Biochemistry, Şanlıurfa, Turkey
2 Dicle University Faculty of Medicine, Department of Biochemistry, Diyarbakır, Turkey
3 Dicle University Faculty of Medicine, Dept Physical Medicine and Rehabilitation, Diyarbakır, Turkey
4 Batman State Hospital, Dept., Physical Medicine and Rehabilitation, Batman, Turkey
5 Dicle University Faculty of Medicine, Dept., Family Medicine, Diyarbakır, Turkey
Yazışma Adresi /Correspondence: Dr. Mustafa Akif Sariyildiz, Dicle University Faculty of Medicine,
Department of Physical Medicine and Rehabilitation, Diyarbakır, Turkey     Email: makifsariyildiz@hotmail.com
Geliş Tarihi / Received: 21.09.2012,  Kabul Tarihi / Accepted: 23.10.2012
Copyright © Dicle Tıp Dergisi 2012, Her hakkı saklıdır / All rights reserved
Dicle Tıp Dergisi /   2012; 39 (4): 479-484
Dicle Medical Journal   doi: 10.5798/diclemedj.0921.2012.04.0186
ORIGINAL ARTICLE / ÖZGÜN ARAŞTIRMA
The relationship between bone mineral density and levels of RANKL, 
osteoprotegerin and cathepsin-K in patients with rheumatoid arthritis
Romatoid artritli hastalarda kemik mineral yoğunluğu ile RANKL, osteoprotegerin ve 
katepsin-K düzeyleri arasındaki ilişki
Gökhan Çakırca1, Nuriye Mete2, Ibrahim Batmaz3, Mustafa Akif Sarıyıldız3, Mehmet Ali Ulu4, 
Levent Yazmalar3, Tahsin Celepkolu5, Remzi Çevik3
ÖZET
Amaç: Bu çalışmanın amacı Romatoid Artrit’li (RA) has-
talarda Osteoprotegerin (OPG), Nükleer faktör kappa B 
reseptör aktivatörü ligandı (RANKL), katepsin-K düzeyle-
rini ve ayrıca bu parametrelerin kemik mineral yoğunluğu 
(BMD) ile ilişkisini araştırmaktır.
Gereç ve yöntem:  Çalışmaya  postmenopozal  sağlıklı 
(n=30), postmenopozal osteoporozlu (n=30) ve postme-
nopoz RA’lı (n=30) toplam 90 olgu alındı. Serum RANKL, 
OPG ve katepsin-K ELİSA yöntemiyle çalışıldı.
Bulgular: Postmenopozal RA’ lı hastalarda serum RANKL 
ve  OPG  seviyeleri  postmenopozal  sağlıklı  kontrollere 
kıyasla  anlamlı  yüksekken,  serum  OPG/RANKL  oranı 
anlamlı düşük bulundu. Bununla birlikte postmenopozal 
RA’lı hastalarda, postmenopozal osteoporozlu hastalara 
göre serum OPG ve OPG/RANKL oranı anlamlı düşük 
iken, serum RANKL seviyesi anlamlı yüksekti. Postme-
nopozal RA’lı hastalarda lomber spine (LS) ve femur neck 
(FN)  kemik  mineral  dansiteleri  (BMD)  ile  OPG/RANKL 
oranı  arasında  pozitif  korelasyon  saptanırken;  RANKL 
düzeyleri ile negatif korelasyon bulundu.
Sonuç:  RANKL/RANK/OPG  sistemi  osteoporoz  ve  RA 
patogenezinde rol alabilmektedir ve OPG/RANKL oranı 
kemik dansitesinin önemli bir belirleyicisi olabilir.
Anahtar kelimeler: Osteoporoz, romatoid artrit, RANKL, 
OPG, Katepsin-K
ABSTRACT
Objectives: The aim of this study was to evaluate the 
levels of osteoprotegerin (OPG), nuclear factor kappa B 
receptor activator ligand (RANKL), cathepsin K in patients 
with rheumatoid arthritis (RA) and the relation between 
these parameters and bone mineral density (BMD).
Materials and methods: Totally 90 cases including 30 
postmenopausal and healthy women, 30 with postmeno-
pausal  osteoporosis  and  30  with  postmenopause  RA 
were enrolled in the study. The serum RANKL, OPG and 
cathepsin K were measured by ELISA method.
Results: The levels of serum RANKL and OPG in the pa-
tients with postmenopausal RA were found significantly 
higher compared to the postmenopausal healthy women 
whereas the rate of serum OPG/RANKL was found sig-
nificantly lower. In addition, the rate of OPG and OPG/
RANKL  were  significantly  lower  in  patients  with  post-
menopausal RA compared to the postmenopausal osteo-
porosis, whereas the level of serum RANKL was signifi-
cantly higher. Positive correlation was detected between 
bone densities of lumbar spine (LS), femur neck (FN) and 
the rate of OPG/RANKL in patients with postmenopausal 
RA. Also negative correlation was detected between LS 
and FN bone densities and RANKL levels.
Conclusions: The system of RANKL/RANK/OPG may 
have a role in osteoporosis and RA pathogenesis and the 
rate of OPG/RANKL might be a significant determiner of 
bone density.
Key words: Osteoporosis, rheumatoid arthritis, RANKL, 
OPG, cathepsin-KG. Çakırca, et al. BMD, RANKL, osteoprotegerin and Cathepsin-K in rheumatoid arthritis 480
Dicle Tıp Derg / Dicle Med J    www.diclemedj.org   Cilt / Vol 39, No 4, 479-484
INTRODUCTION
Osteoporosis (OP) is a disease of muscle skeleton 
system which is characterized by the increase of 
possibility of bone fragility and fracture as a result 
of low bone mass and deterioration of microarchi-
tecture form of bone tissue.1 It is necessary to make 
a multilateral evaluation on bone metabolism so as 
to diagnose, cure and observe OP. In addition to 
radiographic methods, biochemical determiners of 
bone circle are used nowadays in order to evaluate 
early diagnosis, clinic progress and feedback of the 
treatment.2
Osteoprotegerin (OPG) functions as a trap re-
ceptor by attaching Nuclear Factor Kappa B Re-
ceptor Activator Ligand (RANKL), which is a key 
mediator of a bone resorption and it prevents the at-
tachment to Nuclear Factor Kappa B Receptor Acti-
vator (RANK). As a result, it prevents RANKL from 
developing bone resorption by inhibiting osteoclast 
differentiation and activation.3 It is important to find 
out new determiners which show bone cycles such 
as OPG/RANK/RANKL in order to cure bone dis-
eases and detect new therapeutic agents.4,5,6
It was shown that OPG/RANK/RANKL have a 
role in not only focal and generalized bone lost but 
also joint inflammation pathophysiology in Rheu-
matoid Arthritis.7,8 It was shown in the studies that 
active T cells are important resources of RANKL in 
inflame synovium, synovial fibroblast and synovial 
tissue.9 Furthermore, the studies specify that the rate 
of OPG/RANKL can be used as a biologic diagnosis 
way for non-malignant pathologies such as osteoly-
sis and bone fractures in relation with osteoporosis, 
ankylosing spondylitis, rheumatoid arthritis, bone 
tumors and hip prosthesis.10
Cathepsin  K  is  a  cysteine  protease  which  is 
necessary for the deterioration of bone matrix pro-
tein component and for the osteoclast functions. It 
is produced with bone resorption macrophages and 
synovial fibroblasts. It has a role in the fragmenta-
tion of osteonectin, type 1and type 2 of collagene 
proteins.11 In addition to that, it has a key role in 
osteoporosis, osteolytic bone metastasis and bone 
remodeling and resorption in RA.12,13
We aimed to evaluate the levels of cathepsin 
K, OPG, RANKL and relation with bone mineral 
density (BMD) in patients with RA.
MATERIALS AND METHODS
The present study had a cross-sectional design ap-
proved by the local ethics committee. All the re-
cruited subjects were approved with an informed 
consent  form  before  participating  in  the  study. 
Ninety cases who applied to the Dicle Faculty of 
Medicine,  Physical  Medicine  and  Rehabilitation 
outpatient clinic between November 2010 and Sep-
tember 2011; 30 recently diagnosed with postmeno-
pausal osteoporosis and did not take antiresorptive 
treatment; 30 healthy female (employee in our hos-
pital) postmenopausal individuals and 30 patients 
diagnosed with RA according to the 1987 American 
College of Rheumatology criteria 14 were included 
in this study; (did not use biologic agents, 20 of 
them were with osteoporosis and 10 of them were 
osteophenic).
Patients  with  thyroid  disease  or  parathyroid 
glands disease, other endocrine disorders, serious 
liver  or  kidney  disease,  radiological  abnormali-
ties (scoliosis, platyspondyly, and others) were ex-
cluded from the study. Patients were also excluded 
if they had concomitant use of estrogen, androgen, 
anticonvulsant or anticoagulant drugs. Other exclu-
sion criteria were alcohol users, smokers, and HIV 
subjects.
Measurement of the clinical variables and 
laboratory tests in patients with RA
The demographic and clinical characteristics of the 
patients such as age, sex, height, weight, education-
al level, the disease duration (which is defined as 
the duration since the onset of the first symptoms 
of RA), degree of morning stiffness, tender-swol-
len  joint  count  and  the  physician’s  and  patient’s 
global assessments were determined. The duration 
of the morning stiffness (minutes), mean pain and 
mean  daytime  fatigue  [100  mm  visual  analogue 
scale (VAS)] were also noted. The disease activity 
(DAS28) scores were evaluated using the disease 
activity score calculator.15 The erythrocyte sedimen-
tation rate (ESR) was measured through the Wester-
gren  method  (mm/h)  and  the  serum  C-reactive 
protein (CRP) level was determined with the help 
of nephelometry (mg/dl). The RF titres were also 
measured through the nephelometric immunoassay 
method (IU/ml).G. Çakırca, et al. BMD, RANKL, osteoprotegerin and Cathepsin-K in rheumatoid arthritis 481
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Sample collection of OPG, RANKL and cathepsin K
Blood  samples  were  obtained  after  an  overnight 
fast. Serum was separated and frozen immediately 
after blood drawing. All the serum were stored at 
-80°C until analysis. Serum concentrations of OPG, 
RANKL and cathepsin K of all individuals were 
both measured by an ELISA. The optical density 
was measured at 450 nm using an automatic ELISA 
reader.
Measurement of BMD
BMD was determined by dual X-ray absorptiom-
etry (DXA) at the lumbar spine (L1-L4; BMD-LS) 
and the femoral neck (BMD-FN). Patients with T 
scores higher than -1.0 at both sites (LS and FN) 
were considered to have normal BMD, those with T 
score of -1 to - 2.5 as patients with osteopenia and 
those with a T score lower than -2.5 at LS and/or FN 
were defined as patients with osteoporosis.
Statistical analysis
The calculations were performed using the Statisti-
cal Package for Social Sciences for Windows soft-
ware version 16.0. The Kolmogorov-Smirnov test 
was used to confirm that data within the ranges of 
normal distribution in both groups. A non-paramet-
ric test was employed for the variables outside the 
normal  distribution.  The  comparison  of  the  data 
between reciprocal groups was carried out through 
the Mann-Whitney U-test. Variance analysis (ANO-
VA) was used for the comparison among multiple 
groups and Tukey HSD test was used so as to find 
the groups which cause the difference at the end of 
the test. Correlations between OPG, RANKL, OPG/
RANKL, BMD and the RA-related variables were 
investigated with the help of Spearman’s correla-
tion. Statistical significance was based on a value of 
p<0.05 with a 95% confidence interval.
RESULTS
Totally 90 cases whose ages were between 42 and 
65 (mean 50.8 ± 11.2) years, were included in this 
study.  Demographic  data  of  the  all  groups  were 
shown in Table 1. Patients with postmenopausal RA 
showed obviously higher plasma levels of RANKL 
compared with other two groups, with a consequent 
significantly  lower  OPG/RANKL.  Whereas  OPG 
level  was  significantly  higher  in  postmenopausal 
RA patients than the postmenopausal healthy group, 
OPG level in the postmenopausal RA patients was 
significantly lower than the ones with OP (table 2). 
Correlation analyses of serum OPG, OPG/RANKL, 
RANKL, Cathepsin K and clinical variables in pa-
tients with postmenopausal RA was demonstrated in 
Table 3. Whereas there was a significantly negative 
correlation between levels of cathepsin K, RANKL 
and BMD, the here was also a significantly positive 
correlation between the rate of OPG/RANKL and 
BMD.
Table 1. Characteristics of patients and controls (mean ± SD)
Postmenopausal RA Postmenopausal Osteoporosis Postmenopousal
Healthy Controls p
Age (years) 63.2 ± 11.43 61.8 ± 10.32 57.1 ± 8.23 NS
Weight (kg) 58.6 ± 13.25 56.5 ± 12.87 55.2 ± 12.34 NS
Height (cm) 155.5 ± 7.45 157.6 ± 9.23 152.7 ± 6.52 NS
BMI (kg/m2) 25.3 ± 6.3 26.7 ± 5.6 25.4 ± 3.8 NS
Disease duration (years) 5.46 ± 4.3 4.5 ± 5.6 _
Pain VAS (cm) 4.48 ± 2.85 _ _
DAS28 4.45 ± 2.1 _ _
ESR (mm/h) 27.68 ± 15.68 _ _
CRP (mg/dl) 4.32 ± 3.90 _ _
RF (IU/ml) 143.68 ± 130.56
VAS visual analog scale, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, RF rheumatoid factor, DAS 
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Table 2. Mean scores of the postmenopausal RA, postmenopausal healthy controls, and postmenopausal OP (mean ± SD)
Postmenopausal
RA
Postmenopausal
Healthy Controls
p
Postmenopausal
RA
Postmenopausal
OP
p
OPG 148.89 ± 40.67 126.66 ± 93.20 <0.001 148.89 ± 40.67 214.09 ± 67.83 <0.001
RANKL 10.83 ± 8.92 2.86 ± 2.65 <0.001 10.83 ± 8.92 5.45 ± 2.58 0.004
OPG/RANKL 22.47 ± 20.43 79.70 ± 86,27 <0.004 22.47 ± 20.43 43.23 ± 22.70 <0.001
Cathepsin-K 29.71 ± 7.85 27.01 ± 9.86 0.260 29.71 ± 7.85 28.99 ± 7.65 0.737
Femur neck BMD 0.60 ± 0.08 0.72 ± 0.11 <0.001  0.60 ± 0.08 0.62 ± 0.10 0.524
Lumbar spine BMD 0.72 ± 0.11 0.92 ± 0.09 <0.001  0.72 ± 0.11 0.69 ± 0.08 0.246
OPG Osteoprotegerin, RANKL receptor activator of nuclear factor kappa B ligand, BMD bone mineral density, RA 
rheumatoid arthritis
study,  whereas  the  rate  of  serum  OPG/RANKL 
was significantly lower and serum RANKL and the 
level of OPG were significantly higher in patients 
with postmenopausal RA in comparison to the post-
menopausal healthy controls. Furthermore, the rate 
of serum OPG and OPG/RANKL were significantly 
lower and the level of serum RANKL was signifi-
cantly higher in patients with postmenopausal RA 
compared to the patients with postmenopausal OP.
Patients with RA are at increased risk for os-
teoporosis and bone fractures.8 Moreover, a positive 
correlation was found out between LS, FN BMD 
and OPG/RANKL in the patients with postmeno-
Table 3.  Coefficiens  (r)  of 
Spearman  correlation  analy-
sis  of  serum  OPG,  RANKL, 
Cathepsin K levels and clini-
cal characteristics in patients 
with postmenopausal RA
Characteristics OPG RANKL OPG/RANKL Cathepsin-K
Age 0.110 0.325** 0.255* 0.205
Disease duration -0.060 0.119 0.012 0.149
Tender joint count 0.079 0.250* 0.121 0.204
Duration of morning stiffness 0.181 0.106 0.139 0.166
Pain VAS 0.155 0.090 0.305** 0.285**
Fatigue VAS -0.190 0.121 0.209* 0.351**
ESR (mm/h) 0.235* 0.300** 0.124 0.177
CRP (mg/dl) 0.276** 0.256* 0.191 0.189
RF -0.193 -0.088 -0.043 0.015
DAS28 0.095 0.243** 0.301**
Femur neck BMD 0.181 -0.369**  0.285** -0.289**
Lomber spine BMD 0.155 -0.361** 0.406** -0.316**
VAS visual analog scale, ESR Erythrocyte sedimentation rate, CRP C-reactive protein, OPG Osteoprotegerin, RANKL 
receptor activator of nuclear factor kappa B ligand, RF rheumatoid factor, DAS disease activity score, RA rheumatoid 
arthritis, BMD bone mineral density
*p<0.05, **p<0.01
DISSCUSSION
The aim of our study was to investigate the rela-
tionship between laboratory markers of bone me-
tabolism and BMD in RA patients with a particular 
focus on serum levels of bone-resorbing cytokines 
such as RANKL and its’ physiological antagonist 
OPG. Especially in patients with RA the assessment 
of correlations between soluble parameters of bone 
metabolism  and  BMD  is  problematical  because 
BMD is a result of bone loss during a relatively 
long period of time, whereas soluble parameters of 
bone metabolism can change in a relatively short 
time and are influenced by disease activity. In our G. Çakırca, et al. BMD, RANKL, osteoprotegerin and Cathepsin-K in rheumatoid arthritis 483
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pausal RA whereas a negative correlation was found 
between the levels of RANKL. It has been suggested 
again that the ratio of OPG/RANKL may be more 
important than single OPG or RANKL in regulating 
osteoclast formation and regulating bone destruc-
tion in RA.16,17 Haugeberg et al.18 reported, for the 
first time, the overall frequency of osteoporosis was 
doubled in the female RA population. In accordance 
with results of Haugeberg, in fact, we also observed 
that bone metabolic status was worse in RA patients 
than  postmenopausal  healty  controls.  Changes 
of overall bone mass in this study were similar to 
other researches.19,20 Moreover, it was also found in 
another study that serum concentrations of OPG, 
RANKL, and OPG/RANKL ratio were significantly 
different among groups of normal, osteopenia, and 
osteoporosis in RA. These differences in RA pa-
tients were confirmed again by multiple linear re-
gression analysis, serum RANKL levels negatively 
related to BMD, in contrast to RANKL, there were 
positive linear correlations between BMD and OPG/
RANKL ratio.21 Data in the literature, with regard to 
such relationship between the OPG/RANKL system 
and BMD in RA, was only reported by Oelzner P et 
al. (20) who found only in RA patients older than 60 
years old, serum RANKL levels showed a negative 
correlation with BMD at the LS and serum OPG/
RANKL ratio did not relate to BMD.
Xu et al. 21 found that age and CRP concentra-
tions were identified as the crucial risk determinants 
of osteoporosis in RA. Also in our study we found 
that ESR, CRP and age were positively correlated 
with serum RANKL levels in RA. Inflammation, 
reflecting  the  activity  of  disease  which  associ-
ated with generalized bone loss in RA in previous 
reports.22 This information is likely to become in-
creasingly important as more bone-directed treat-
ments become part of RA management paradigms. 
Thus, denosumab, a monoclonal antibody directed 
against RANKL, should suppress bone loss in RA 
and could be a potential target for novel therapeutic 
agents.23
Proinflammatory  cytokines  like  interleukin-1 
and  tumor  necrosis  factor  alpha  induce  an  over 
expression  of  cathepsin  K,  which  is  responsible 
for increased bone resorption and skeletal compli-
cations in RA.  Bone resorption and formation is 
a well-balanced system and is mediated by osteo-
clasts. Cathepsin K is essential for bone resorption, 
which depends on the production of cathepsin K by 
osteoclasts and its secretion into the extracellular 
department.24 In our study, we found out a negative 
correlation between cathepsin K and LS, FN BMD 
in the patients with RA. It may result from the fact 
that cathepsin K kas a role bone resorption.
The  limitation  of  the  present  study  was  its 
cross-sectional design. Finally, although this study 
is  somewhat  limited  in  statistical  power  because 
of the small sample size and further studies with 
a greater number of patients are needed. Another 
limitation of the study was that the relation between 
the remedies used for RA (for instance DMARD, 
corticosteroid)  and  OPG,  RANKL,  cathepsin  K 
could not be evaluated. It should not be forgotten 
that medicine such as methotrexate and corticoste-
roid may cause decrease in BMD as well.
In conclusion, present study demonstrates that 
the OPG/RANKL system represents an important 
mediator of bone resorption in RA-induced osteo-
porosis. Besides, we found out that the levels of ca-
thepsin K and RANKL are related to BMD in the 
patients with RA. The close follow-up of the levels 
of OPG/RANKL, RANKL and cathepsin K in the 
early RA patients may be a messenger of a possible 
osteoporosis in these patients.
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